EXTEND: Extending the time for Thrombolysis in Emergency Neurological Deficits

Print

Phase III, randomised, multicentre, double blinded, placebo controlled trial (2 arm with 1:1 randomisation) within a larger cohort study of ischaemic stroke patients. Patients randomised to treatment will be stratified for time of randomisation after stroke to within <6 hours and 6-9 hours. The primary hypothesis being tested in this trial is that ischaemic stroke patients selected with significant penumbral mismatch (measured by MRI criteria) at 3 - 9 hours post onset of stroke will have improved clinical outcomes when given intravenous tissue plasminogen activator (tPA) compared to placebo.

A total of 400 participants shall be recruited.    

Extend Investigators in China

Last Updated ( Tuesday, 25 August 2015 13:14 )